TY - JOUR
T1 - The NAME trial
T2 - a direct comparison of classical oral Navelbine versus Metronomic Navelbine in metastatic breast cancer
AU - Langkjer, Sven Tyge
AU - Kenholm, Julia
AU - Jensen, Jeanette Dupont
AU - Wedervang, Kim
AU - Brixen, Annette Torbøl
AU - Grunnet, Mie
AU - Stenbygaard, Lars
AU - Gilje, Bjørnar
AU - Danø, Hella
AU - Glavicic, Vesna
AU - Jacobsen, Erik Hugger
AU - Brems-Eskildsen, Anne Sofie
AU - Kruse, Helle Lemvig
AU - Dongsgaard, Trine
AU - Neimann, Jeppe
AU - Geisler, Jürgen
PY - 2019/8
Y1 - 2019/8
N2 - Chemotherapy for metastatic breast cancer (MBC) is in general given in cycles of maximum tolerated doses to potentially maximize the therapeutic outcome. However, when compared with targeted therapies for MBC, conventional and dose intensified chemotherapy has caused only modest survival benefits during the recent decades, often compromising the quality of life considerably. Navelbine is an antineoplastic agent that has shown efficacy in the treatment of a variety of cancer types, including breast cancer. Early clinical trials involving both breast cancer and lung cancer patients suggest that metronomic dosing of Navelbine might be at least as effective as classical administration (once weekly, etc.). The NAME trial compares these two strategies of Navelbine administration in MBC patients.
AB - Chemotherapy for metastatic breast cancer (MBC) is in general given in cycles of maximum tolerated doses to potentially maximize the therapeutic outcome. However, when compared with targeted therapies for MBC, conventional and dose intensified chemotherapy has caused only modest survival benefits during the recent decades, often compromising the quality of life considerably. Navelbine is an antineoplastic agent that has shown efficacy in the treatment of a variety of cancer types, including breast cancer. Early clinical trials involving both breast cancer and lung cancer patients suggest that metronomic dosing of Navelbine might be at least as effective as classical administration (once weekly, etc.). The NAME trial compares these two strategies of Navelbine administration in MBC patients.
KW - Administration, Intravenous
KW - Administration, Metronomic
KW - Adult
KW - Aged
KW - Antineoplastic Combined Chemotherapy Protocols/administration & dosage
KW - Breast Neoplasms/drug therapy
KW - Drug Administration Routes
KW - Female
KW - Humans
KW - Maximum Tolerated Dose
KW - Middle Aged
KW - Neoplasm Metastasis
KW - Quality of Life
KW - Vinblastine/administration & dosage
KW - Vinorelbine/administration & dosage
U2 - 10.2217/fon-2019-0124
DO - 10.2217/fon-2019-0124
M3 - Journal article
C2 - 31215242
SN - 1479-6694
VL - 15
SP - 2561
EP - 2569
JO - Future oncology (London, England)
JF - Future oncology (London, England)
IS - 22
ER -